Bladder cancer trials distinguish non-muscle-invasive disease (often BCG-related) from muscle-invasive and metastatic urothelial cancer. Antibody-drug conjugates and checkpoint drugs appear frequently. Stage and prior BCG failure rules live on the NCT page. Sourced from ClinicalTrials.gov. Not a recommendation to join any study.
RecruitingNot a traditional drug phaseBethesda, Maryland
Evaluation for NCI Surgery Branch Clinical Research ProtocolsBackground: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols.
NCT00001823 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
RecruitingNot a traditional drug phaseBethesda, Maryland
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant DiseaseSelected individuals suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the time of the initial visit and at periodic intervals during the course of the disease.
NCT00026884 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
RecruitingPhase 2Birmingham, Alabama
Phase 2: testing Cabozantinib S-malate for Bladder AdenocarcinomaThis phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT03866382 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
RecruitingNot a traditional drug phaseAnchorage, Alaska
Not a traditional drug phase: Questionnaire Administration for Acute Lymphoblastic LeukemiaThis study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.
NCT05334069 · Official ClinicalTrials.gov record · Alliance for Clinical Trials in Oncology
RecruitingNot a traditional drug phaseDuarte, California
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual DiseaseThis is an watch-and-measure (no experimental treatment required) case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid.
NCT05366881 · Official ClinicalTrials.gov record · Adela, Inc
RecruitingPhase 1Tucson, Arizona
Phase 1: testing Vepugratinib for Urinary Bladder NeoplasmsThe main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer. Vepugratinib may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene).
NCT05614739 · Official ClinicalTrials.gov record · Eli Lilly and Company
RecruitingNot a traditional drug phaseWashington D.C., District of Columbia
Not a traditional drug phase: Questionnaires for Non-Muscle Invasive Bladder CancerThis study wants to evaluate mood changes in patients with Non-Muscle Invasive Bladder Cancer who are receiving intravesical Bacillus Calmete-Guerin (BCG). Patients with Non-Muscle Invasive Bladder Cancer receiving intravesical treatments are eligible to participate in this study.
NCT05672615 · Official ClinicalTrials.gov record · Johns Hopkins University
RecruitingNot a traditional drug phaseWashington D.C., District of Columbia
Not a traditional drug phase: Prostate capsule-sparing radical cystectomy for Bladder CancerThe purpose of this clinical trial is to determine if prostate-capsule-sparing cystectomy improves functional outcomes without comprising oncologic outcomes in male patients receiving a radical cystectomy. Patients will be randomly assigned to one of two groups: prostate capsule-sparing radical cystectomy or nerve-sparing radical cystectomy.
NCT05792722 · Official ClinicalTrials.gov record · Johns Hopkins University
RecruitingPhase 1Los Angeles, California
Phase 1: testing MGC026 Dose Escalation for Advanced Solid TumorThe study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion in Module A of the study. Combination therapy with pembrolizumab will occur in Module B of the study Participants will receive vobramitamab tavatecan by intravenous (IV) infusion.
NCT06242470 · Official ClinicalTrials.gov record · MacroGenics
RecruitingNot a traditional drug phaseShatin
Not a traditional drug phase: En-Bloc Resection of Bladder Tumours for Bladder CancerThis is a prospective, single-arm study to measure the feasibility and safety of performing transurethral en-bloc resection of bladder tumours using the Zenith robotic system.
NCT06281080 · Official ClinicalTrials.gov record · Chinese University of Hong Kong
RecruitingPhase 3Little Rock, Arkansas
Phase 3: testing Gemcitabine for Non-Muscle Invasive Bladder NeoplasmsThe main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
NCT06319820 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC
RecruitingNot a traditional drug phaseChongqing, Chongqing Municipality
Not a traditional drug phase: Deep learning system for prognostication prediction in bladder cancer for Bladder CancerBladder cancer (BLCA), with its diverse histopathological features and varying patient outcomes, poses significant challenges in diagnosis and prognosis. Postoperative survival stratification based on radiomics feature and whole slide image feature may be useful for treatment decisions to improve prognosis.
NCT06389019 · Official ClinicalTrials.gov record · Mingzhao Xiao
RecruitingPhase 1Duarte, California
Phase 1: testing LY4052031 for Metastatic Solid TumorThis study wants to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion).
NCT06465069 · Official ClinicalTrials.gov record · Eli Lilly and Company
RecruitingPhase 2Bethesda, Maryland
Phase 2: testing [18F]FAPI-74 for SarcomaBackground: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. \[18F\]FAPI-74 is a new PET (positron emission tomography) tracer, a substance that is injected into a person s body before an imaging scan.
NCT06503146 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
RecruitingPhase 2Birmingham, Alabama
Phase 2: testing BAY2927088 for Advanced Solid TumorsResearchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.
NCT06760819 · Official ClinicalTrials.gov record · Bayer
RecruitingPhase 2Tucson, Arizona
Phase 2: testing Cisplatin for Non-Muscle Invasive Bladder Urothelial CarcinomaThis phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
NCT06770582 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
RecruitingPhase 3Sun City, Arizona
Phase 3: testing TAR-210 for Non-Muscle Invasive Bladder NeoplasmsThe main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or symptoms of the cancer returning, or progressing) between Bacillus Calmette-Guérin (BCG) treated participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of high-risk non-muscle-invasive bladder cancer (HR-NMIBC).
NCT06919965 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC
RecruitingNot a traditional drug phaseDijon, Côte D'or
Not a traditional drug phase: Adaptive radiotherapy for Bladder CancerTrimodal therapy (TMT) consisting of transurethral resection of bladder tumors followed by radiotherapy and chemotherapy is a therapeutic alternative in patients with Muscle-Infiltrating Bladder Cancer who are inoperable or refuse surgery. One of the main challenges of TMT is the planning and delivery of radiation therapy.
NCT07043543 · Official ClinicalTrials.gov record · Institut du Cancer de Montpellier - Val d'Aurelle
RecruitingNot a traditional drug phaseDublin, California
Not a traditional drug phase: Exercise intervention for Localized Malignant Solid NeoplasmThis clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength.
NCT07059884 · Official ClinicalTrials.gov record · Alliance for Clinical Trials in Oncology
RecruitingPhase 2Birmingham, Alabama
Phase 2: testing Pembrolizumab for Muscle Invasive Bladder Urothelial CarcinomaThis phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with muscle invasive bladder cancer. Standard of care therapy includes chemotherapy before surgery (neoadjuvant) to shrink or get rid of the tumor.
NCT07061964 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
RecruitingPhase 1Duarte, California
Phase 1: testing PF-08046876 for Advanced/Metastatic Solid TumorsThe purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'.
NCT07090499 · Official ClinicalTrials.gov record · Pfizer
RecruitingNot a traditional drug phaseBurlington, Massachusetts
Not a traditional drug phase: UroAmp Test (Convergent Genomics, Inc.) for Non-muscle Invasive Bladder Cancer (NMIBC)The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.
NCT07187063 · Official ClinicalTrials.gov record · Lahey Clinic
RecruitingNot a traditional drug phaseNanchang, Anhui
Not a traditional drug phase: Second Transurethral Resection of Bladder Tumor (re-TURBT) for Bladder CancerNon-muscle-invasive bladder cancer (NMIBC) accounts for approximately 75% of newly diagnosed bladder cancers and is characterized by a high risk of recurrence and progression. Current guidelines recommend that patients with stage T1 NMIBC undergo a second transurethral resection of bladder tumor (re-TURBT) within 2-6 weeks after the initial surgery to remove residual tumor, confirm staging, and obtain additional pathological information.
NCT07187635 · Official ClinicalTrials.gov record · Tianjin Medical University Second Hospital
RecruitingPhase 1Birmingham, Alabama
Phase 1: testing PF-08052667 for Non-muscle Invasive Bladder CancerThis study wants to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab. This study is for adults who have a type of bladder cancer that hasn't spread into the muscle layer of the bladder but is more likely to come back or grow.
NCT07206225 · Official ClinicalTrials.gov record · Pfizer
RecruitingPhase 1 / Phase 2Bakersfield, California
Phase 1 / Phase 2: testing MK-3120 for Bladder CancerResearchers are looking for new ways to treat high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder and has not spread to the bladder muscle or outside of the bladder.
NCT07222488 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC
RecruitingNot a traditional drug phaseBirmingham, Alabama
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder …This study wants to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer or until the signs and symptoms of cancer occur again (disease-free survival) in participants with non-muscle invasive bladder cancer (NMIBC; an early-stage bladder cancer that is limited to the inner lining of bladder).
NCT07309445 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC
RecruitingPhase 3Newport Beach, California
Phase 3: testing Sacituzumab tirumotecan for Bladder CancerResearchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy.
NCT07419295 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC
RecruitingPhase 2Bethesda, Maryland
Phase 2: testing TriAdeno vaccine for AdenocarcinomaBackground: Prostate cancer is the second most common cause of cancer-related death among men in the United States. Early-stage, low-grade prostate cancer is managed with active monitoring.
NCT07574541 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
RecruitingNot a traditional drug phaseSuwon
A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmett…This study wants to assess participant's overall well-being and the extent to which medical services are used by participants with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) who have received Bacillus Calmette-Guérin (BCG) therapy. HR-NMIBC is a type of bladder cancer in which cancer is confined to the inner lining of the bladder and has a high risk of returning or becoming more serious.
NCT07735793 · Official ClinicalTrials.gov record · Janssen Korea, Ltd., Korea
RecruitingPhase 3Kaohsiung City
Phase 3: testing Sac-TMT for Bladder CancerResearchers are looking for new ways to treat muscle-invasive bladder cancer (MIBC). MIBC is a type of bladder cancer that has spread into the muscle layer of the bladder but has not spread to other distant parts of the body.
NCT07829783 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC
RecruitingPhase 3Macon, Georgia
Phase 3: testing T-Bren, Dose level 1 for Urothelial CancerThe objective of the study is to measure the how well it works and safety of T-bren in participants with HER2 expressing metastatic UC with progression on or after anti-PD-(L)1-based therapy.
NCT07869836 · Official ClinicalTrials.gov record · SystImmune Inc.